On February 9, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022 (Press release, Selecta Biosciences, FEB 9, 2022, View Source [SID1234607914]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Leerink 11th Annual Global Healthcare conference
Format: Presentation and one-on-one investor meetings
Presentation Date: Friday February 18th, 2022
Presentation Time: 1:00 p.m. EST
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

On February 9, 2022 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that it will webcast its Quarterly Update Conference Call for the fourth quarter 2021 on Tuesday, February 22 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the fourth quarter and year ended December 31, 2021, following the close of trading (Press release, Halozyme, FEB 9, 2022, View Source [SID1234607913]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To register for this conference call, please use this link: View Source After registering, you will receive an email confirmation that includes dial in details and unique conference call codes for entry. Registration is open through the live call. However, to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

The call will be webcast live through the "Investors" section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit the Investor’s page of www.halozyme.com approximately 15 minutes prior to the call to register, download and install any necessary audio software. A telephone replay will be available for two weeks after the call by dialing (800) 770-2030 (domestic callers) or (647) 362-9199 (international callers) using replay ID number 44868.

On February 9, 2022 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported that management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference (Press release, Harpoon Therapeutics, FEB 9, 2022, View Source [SID1234607912]). The discussion will take place on Wednesday, February 16, 2022 at 5 p.m. ET (2 p.m. PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com with an archived replay available following the event.

On February 9, 2022 Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, reported that the Company will be presenting at the 2022 BIO CEO & Investor Conference being held February 14-17, 2022 (Press release, Synthetic Biologics, FEB 9, 2022, View Source [SID1234607911]). The conference will be conducted as a hybrid event at the New York Marriott Marquis and virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steven Shallcross, Chief Executive Officer and Chief Financial Officer of Synthetic Biologics is scheduled to present on Tuesday February 15, 2022 at 11:00 AM Eastern Time. Management will also be available to participate in 1×1 meetings with qualified investors throughout the conference. Synthetic’s presentation will be made available on their website at View Source

On February 9, 2022 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported that company management will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference, which is being held in a virtual format February 14-18, 2022 (Press release, Crinetics Pharmaceuticals, FEB 9, 2022, View Source [SID1234607909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Date: Wednesday, February 16, 2022
Time: 1:00 p.m. Eastern Time
Webcast Link: View Source
In addition, the live and archived presentation will be accessible on the Events & Presentations page in the Investors section on the Company’s website.